Felzartamab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Antibody-Mediated Rejection (AMR). According to Globaldata, it is involved in 9 clinical trials, of which 3 were completed, 5 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Felzartamab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Felzartamab is expected to reach an annual total of $3 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Felzartamab is under development for the treatment of late antibody-mediated renal allograft rejection, IgA nephropathy (IgAN), membranous nephropathy(anti-PLA2R antibody-positive membranous nephropathy), refractory/relapsed multiple myeloma. The drug candidate is administered as an intravenous infusion. It is a fully human monoclonal antibody (mAb) directed against CD38, which is one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells.
It was also under development for the treatment of non-small lung cancer, systemic lupus erythematosus.
I-Mab is a biopharmaceutical company. It develops transformational medicines for therapeutic areas of immuno-oncology and autoimmune diseases. Its pipeline product portfolio comprises TJ202, a CD38 antibody for treating multiple myeloma; TJ101, a recombinant human growth hormone (rhGH) used in pediatric patients with growth hormone deficiency; TJ301, an IL-6 inhibitor for ulcerative colitis; enoblituzumab, a B7-H3 antibody against tumors; and TJ107, an oncology care agent to treat cancer treatment-related lymphopenia. I-Mab utilizes various molecular engineering platforms to develop drug molecules with defined biological properties. The company collaborates with biotechnology companies, CROs, and CMOs to advance the clinical development of its pipeline assets and out-licensing opportunities. It operates in China, Hong Kong and the US. I-Mab is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY221.6 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of CNY88 million in FY2021. The operating loss of the company was CNY1,969.5 million in FY2022, compared to an operating loss of CNY2,071.3 million in FY2021. The net loss of the company was CNY2,507.3 million in FY2022, compared to a net loss of CNY2,331.5 million in FY2021.
For a complete picture of Felzartamab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.